Cannabis and Driving: Peer-Reviewed Research Consensus

251 studies analyzedLast updated March 7, 2026

Overview

The research base for cannabis and driving includes 251 peer-reviewed studies spanning 1976–2026. Of these, 45 provide strong evidence, including 6 meta-analyses and 46 randomized controlled trials. Key findings with strong support include: meta-analysis of 9 studies found cannabis nearly doubles motor vehicle crash risk (or 1, and a meta-analysis of 80 studies found thc impairs driving-related skills at peak effect, with impairment from inhaled cannabis generally resolving within 3-5 hours. However, several findings remain debated, and the evidence is not uniform across all areas. Many studies have methodological limitations including small sample sizes, short follow-up periods, and reliance on self-reported data.

What the Research Shows

Findings supported by multiple peer-reviewed studies. Stronger evidence means more consistency across study types.

Meta-analysis of 9 studies found cannabis nearly doubles motor vehicle crash risk (OR 1

Strong Evidence
18 studies|High heterogeneity between studies. Observational designs cannot prove causation. Different studies used different measures of cannabis exposure (blood THC vs self-report). Publication bias was possib

A meta-analysis of 80 studies found THC impairs driving-related skills at peak effect, with impairment from inhaled cannabis generally resolving within 3-5 hours

Strong Evidence
18 studies|Laboratory and simulated driving conditions may not fully replicate real-world driving. Most studies used moderate, controlled doses. Individual variation in tolerance and metabolism is not captured.

Meta-analysis of 28 studies found blood and saliva THC levels are poor predictors of driving impairment, with negligible to weak correlations that disappear entirely in regular cannabis users

Strong Evidence
18 studies|Analyses in regular users were less robust due to fewer studies. Most studies used simulated rather than real-world driving.

Where Scientists Disagree

Areas where research shows conflicting results or ongoing scientific debate.

Among 600 drivers killed in single-vehicle crashes, alcohol was detected in 79

Moderate Evidence
55 studies|Detection of THC in blood does not prove impairment at the time of the crash. THC metabolites clear the blood relatively quickly, so some cannabis-impaired drivers may have tested negative. The study

THCV-COOH, a urinary metabolite unique to natural marijuana, reliably distinguished marijuana use from prescription Marinol use in a controlled crossover study

Moderate Evidence
55 studies|Only four subjects. THCV content varies among marijuana varieties, so very low-THCV marijuana might not produce detectable THCV-COOH. The study predates the availability of many modern cannabis produc

European review found illicit drug prevalence of 1-5% among drivers, with cannabis among the top substances of concern

Moderate Evidence
55 studies|The review focused on the Finnish and European context, which may not generalize to other regions. Data on drug prevalence among drivers varied in quality across countries. The review did not establis

Two studies in an unventilated van found passive cannabis smoke exposure only caused positive oral fluid tests when samples were collected in the smoky environment

Moderate Evidence
55 studies|The extreme exposure conditions (unventilated van with four simultaneous smokers) may not represent typical passive exposure scenarios. Only oral fluid testing was examined. The sample size of passive

What We Still Don't Know

  • Long-term prospective studies tracking outcomes over 5+ years are largely absent from the literature.
  • Research on diverse populations (different ages, ethnicities, and medical backgrounds) remains limited.

Evidence Breakdown

Distribution of study types in this research area. Higher-tier evidence (meta-analyses, RCTs) provides stronger conclusions.

Meta-Analyses & Systematic Reviews(Tier 1)
6 (2%)
Randomized Controlled Trials(Tier 2)
46 (18%)
Observational & Cohort(Tier 3-4)
100 (40%)
Reviews & Scoping(Tier 4)
39 (16%)
Case Reports & Animal(Tier 5)
4 (2%)
Other
56 (22%)

Key Studies

The most impactful research in this area.

Blood and Saliva THC Levels Are Poor Indicators of Driving Impairment

Many jurisdictions use blood or oral fluid THC levels to identify impaired drivers, similar to blood alcohol. This meta-analysis shows THC biomarkers are fundamentally different from blood alcohol as impairment indicators.

2022

Roadside Oral Fluid THC Tests Are Good at Detecting Any Cannabis Use but Poor at Predicting Blood Levels

Many countries use roadside oral fluid tests to enforce cannabis-impaired driving laws. This study shows these tests are useful for identifying recent cannabis use but unreliable for determining whether drivers exceed legal blood THC limits, with major implications for enforcement fairness.

2022

Meta-analysis of 57 studies confirmed cannabis impairs driving, comparable to low blood alcohol

This is the largest meta-analysis of experimental driving studies on cannabis to date, providing definitive evidence that cannabis impairs driving performance and that the combination with alcohol is particularly dangerous.

2022

THC impairs driving-related skills for about 3-5 hours after inhaling, longer after eating

As cannabis legalization expands, evidence-based guidelines for how long to wait before driving are essential. This meta-analysis provides the most comprehensive synthesis to date of how long THC-related driving impairment actually lasts.

2021

Meta-analysis: cannabis use nearly doubles motor vehicle crash risk

This was one of the most comprehensive meta-analyses of cannabis-impaired driving risk. The near-doubling of crash risk provided a clear evidence base for policy on drug-impaired driving.

2012

Cannabis Use Linked to Higher Risk of Fatal and Injurious Car Crashes

As cannabis legalization expands globally, quantifying the crash risk associated with cannabis use is essential for setting driving policy, THC legal limits, and public education campaigns.

2025

Research Timeline

How our understanding of this topic has evolved.

Pre-2000

4 studies published. Includes 2 RCTs.

2000–2009

9 studies published. Includes 4 RCTs, 1 strong-evidence studies.

2010–2014

22 studies published. Includes 1 meta-analyses, 6 RCTs, 2 strong-evidence studies.

2015–2019

43 studies published. Includes 6 RCTs, 10 strong-evidence studies.

2020–present

173 studies published. Includes 5 meta-analyses, 28 RCTs, 32 strong-evidence studies.

About This Consensus

This consensus synthesizes 251 peer-reviewed studies: 6 meta-analyses (2%), 46 randomized controlled trials (18%), 100 observational studies (40%), 39 reviews (16%), 4 case studies (2%), 56 other study types (22%). Studies span from the earliest available research through 2025. Evidence strength ratings reflect study design, sample size, and replication across multiple research groups.

This page synthesizes findings from 251 peer-reviewed studies. It is not medical advice. Always consult a healthcare provider for personal health decisions.